JNJ · Earnings call · 2026Q3T · Full report

Milvexian Market Opportunity

JOHNSON & JOHNSON · 2026-10-13 · Importance 31 · Surprise 42

Johnson & Johnson remains confident in milvexian’s ongoing secondary-stroke and atrial-fibrillation studies, citing its higher factor XI inhibition potency and safety margin for dose optimization. Management expects secondary-stroke data potentially this year and atrial-fibrillation data the following year. The company highlighted substantial unmet demand for effective oral anticoagulation with lower bleeding risk, noting that approximately 40% of atrial-fibrillation patients eligible for oral anticoagulants do not receive them.